Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214825 · ClinicalTrials.gov registry record · NA
Aldosterone and Vascular Disease in Diabetes Mellitus
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT00214825 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 46 participants.
The verdict
NCT00214825, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
Specific aims for this proposal are to determine in patients with diabetes mellitus the effects of an aldosterone receptor antagonist on: 1. Coronary microvascular function assessed by MRI perfusion reserve, 2. Endothelial dysfunction assessed by brachial artery reactivity studies, and 3. Inflammation assessed by blood measurements of c-reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor-1 (PAI-1).
Interventions
- DRUG Hydrochlorothiazide
- DRUG eplerenone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-08 |
| Est. Completion | 2006-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214825
The ClinicalTrials.gov registry entry for NCT00214825 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydrochlorothiazide is the first listed.
NCT00214825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00214825 about?
NCT00214825 is a clinical study titled "Aldosterone and Vascular Disease in Diabetes Mellitus". Specific aims for this proposal are to determine in patients with diabetes mellitus the effects of an aldosterone receptor antagonist on: 1. Coronary microvascular function assessed by MRI perfusion reserve, 2. Endothelial dysfunction assessed by brachial artery reactivity studies, and 3. Inflammat...
What is the current status of trial NCT00214825?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2003-08. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00214825?
The interventions under investigation include: Hydrochlorothiazide (DRUG), eplerenone (DRUG).
Who is sponsoring clinical trial NCT00214825?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.